European Autism Interventions – A Multicentre Study for Developing New Medications (EU-AIMS) – is the largest single grant for autism in the world, and the largest for the study of any mental health disorder in Europe.

EU-AIMS involves a novel collaboration between organisations representing affected individuals and their families (Autism Speaks), academia and Industry who for the first time in the world have come together to develop the infrastructure underpinning new treatments for autism. Patient organizations, academic and industry join forces to develop and assess novel treatment approaches for autism.

Eva Loth, Kings College London, discusses EU-AIMS

Image courtesy of interviewee. October 24, 2017